secwatch.observer — SEC 8-K summary
======================================

Issuer:     PROTHENA CORP PUBLIC LTD CO (PRTA)
CIK:        0001559053
Form:       8-K
Filed at:   2025-02-20T23:59:59+00:00
Accession:  0001559053-25-000003
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prothena reports FY2024 net loss $122.3M; cash $472.2M; AFFIRM-AL topline expected Q2 2025
--------------------------------------------------------------------------------

- Net loss per share Q4 $1.08, FY2024 $2.27; total revenue FY2024 $135.2M (up from $91.4M prior year).
- Cash $472.2M at Dec 31, 2024, no debt; 2025 guidance: net cash burn $168-175M, year-end cash ≈$301M.
- Confirmatory Phase 3 AFFIRM-AL (birtamimab) topline results expected Q2 2025; SPA with FDA, primary endpoint all-cause mortality.
- PRX012 Phase 1 ASCENT readouts starting mid-2025; BMS started Phase 2 for BMS-986446; $80M received for PRX019 license.
- Roche's prasinezumab Phase 2b PADOVA missed primary endpoint but showed trends; Roche to discuss next steps with health authorities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1559053/000155905325000003/0001559053-25-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1559053/000155905325000003/prta-20250220.htm
  HTML page:      https://secwatch.observer/filing/0001559053-25-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer